At a glance
ClinicalIndex Comparison RecordN/ACompleted· 38 enrolled
Drug / intervention
Spironolactone +1 moredrug
Likely dose
Spironolactone 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications
In Brief
A clinical study evaluating Spironolactone and Placebo for Obesity and Insulin Resistance. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to find out whether spironolactone causes changes in levels of insulin and markers of inflammation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Insulin Resistance
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedJul 2011
Primary CompletionAug 2013
Study CompletionDec 2013
TodayJul 2026
First PostedJul 29, 2011
Enrollment StartFeb 1, 2009
Primary CompletionAug 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 14.9 years ago
Interventions
Spironolactonedrug
50 mg once daily for 6 weeks.
Placebodrug
Placebo-matching spironolactone once daily for 6 weeks.